Esomac D 20 Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 20 mg, designed for the effective management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Esomeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting mucosal healing. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, providing symptomatic relief from nausea, vomiting, and bloating associated with delayed gastric emptying or gastroparesis. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. Esomac D 20 Capsule SR is indicated for patients requiring combined acid suppression and prokinetic therapy, particularly in cases where monotherapy is insufficient. It should be used under medical supervision, with caution advised in patients with cardiac conditions due to Domperidone’s potential to prolong the QT interval. Common side effects may include headache, dry mouth, or abdominal discomfort. Contraindications include known hypersensitivity to either component and concurrent use with medications that prolong QT interval. Proper dosing and duration should be adhered to as per prescribing information to optimize therapeutic outcomes.